Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research report report published on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.

Evogene Trading Down 5.7 %

Shares of EVGN stock opened at $1.33 on Friday. The stock has a market capitalization of $7.14 million, a price-to-earnings ratio of -0.30 and a beta of 1.29. Evogene has a twelve month low of $1.20 and a twelve month high of $10.00. The stock has a fifty day simple moving average of $1.59 and a two-hundred day simple moving average of $2.09.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC bought a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned approximately 0.30% of Evogene at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.